![Anders Tuv](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anders Tuv
Gründer bei
Zelluna Immunotherapy AS
Vermögen: 143 752 $ am 30.06.2026
Profil
Anders Tuv is the founder of Zelluna Immunotherapy AS, serving as Non-Executive Director since 2016.
Current jobs include Chairman at Zelluna ASA since 2025, Investment Director at Radiumhospitalets Forskningsstiftelse, Director at Artbio.
AS since 2019, Director at Nordovo Biosciences AS since 2024, Director at Nextera AS since 2012, Non-Executive Director at Nucligen AS, Investment Director at Radforsk Investeringsstiftelse since 2011, and Director at Ondosis AB since 2021.
Former jobs include Chairman at OncoImmunity AS from 2016 to 2019, Director at Oslo Cancer Cluster NCE, Independent Director at Photocure ASA, Director at Nykode Therapeutics ASA from 2021 to 2024, and Managing Consultant at Ernst & Young AS.
Education includes a graduate degree from BI Norwegian Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2024 | 325’000 ( 0.1% ) | 105 755 $ | 30.06.2026 | |
0.07% | 31.12.2025 | 20’000 ( 0.07% ) | 37 997 $ | 30.06.2026 |
Aktive Positionen von Anders Tuv
| Unternehmen | Position | Beginn |
|---|---|---|
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Direktor/Vorstandsmitglied | 01.01.2012 |
Radiumhospitalets Forskningsstiftelse
 Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Chief Investment Officer | - |
Zelluna Immunotherapy AS
 Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Gründer | 01.01.2016 |
Radforsk
 Radforsk Financial ConglomeratesFinance Operates as a life science investment company | Chief Investment Officer | 01.01.2011 |
Nucligen AS | Direktor/Vorstandsmitglied | - |
Artbio AS
 Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Direktor/Vorstandsmitglied | 01.04.2019 |
Ondosis AB
 Ondosis AB Pharmaceuticals: MajorHealth Technology Develops prescription regimens | Direktor/Vorstandsmitglied | 01.06.2021 |
Nordovo Biosciences AS
 Nordovo Biosciences AS BiotechnologyHealth Technology Operates as biotechnology company | Direktor/Vorstandsmitglied | 01.06.2024 |
Ehemalige bekannte Positionen von Anders Tuv
| Unternehmen | Position | Ende |
|---|---|---|
| NYKODE THERAPEUTICS | Vorsitzender | 22.12.2021 |
| ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░░░ ░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░ ░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Anders Tuv
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
17
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Operates as oncology research firm, which develops cancer diagnostics and medicines | Commercial Services |
Photocure ASA
 Photocure ASA Medical SpecialtiesHealth Technology Develops and sells pharmaceuticals and medical devices | Health Technology |
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Finance |
BI Norwegian Business School
 BI Norwegian Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ernst & Young AS
 Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
Nykode Therapeutics ASA
 Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Commercial Services |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Health Technology |
OncoImmunity AS
 OncoImmunity AS Packaged SoftwareTechnology Services Develops software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers | Technology Services |
Ondosis AB
Ondosis AB Pharmaceuticals: MajorHealth Technology Develops prescription regimens | Health Technology |
Nucligen AS | |
Radforsk
Radforsk Financial ConglomeratesFinance Operates as a life science investment company | Finance |
Nordovo Biosciences AS
Nordovo Biosciences AS BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Artbio AS
Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Health Technology |
Wählen Sie MarketScreener 
